fda warning letters compounded semaglutide tirzepatide 2024 2025 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA warns against compounded versions

Semaglutide, originally developed for type 2 diabetes, has been recognized for its potential impact on weight

T., & McIntyre, R

Corrects glutathione deficiencies (associated with aging)

The Times story described patients using alternative sources for these drugs (telehealth companies) who used compounding pharmacies to prepare much smaller doses than the branded options marketed by the drug companies

Both drugs contain tirzepatide as the active ingredient, but Mounjaro is approved to treat Type 2 diabetes, while Zepbound is approved for weight loss and obstructive sleep apnea in adults with obesity

These target specific organ systems and have a unique mechanism involving gene expression modulation